Valion Bio Profit Margin

The latest profit margin for VBIO is 6328.21% as of June 2026. That compares with -1372.51% in the prior-year period — up 561.1% year over year. That is above the sector sector average of 21.34%. Investors often review this figure alongside Valion Bio's historical trend and sector peers before judging valuation or financial health.

Over the past year, VBIO's profit margin moved from -1372.51% to 6328.21% — a 561.1% year-over-year increase. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Valion Bio's valuation or profitability profile.

Against its sector companies, VBIO currently prints 6328.21% for profit margin, while the sector average sits near 21.34%. That is roughly 29551.6% above the sector mean. Large gaps often invite a closer look at Valion Bio's growth, margins, and balance sheet.

Profit Margin shows how effectively Valion Bio converts resources into returns. At 6328.21%, VBIO may look efficient or underperforming depending on peer benchmarks and trend direction. That compares with -1372.51% in the prior-year period — up 561.1% year over year. Pair the percentage with revenue growth and leverage for a fuller health check.

After noting VBIO's profit margin (6328.21%), review year-over-year change from -1372.51%, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.